187 related articles for article (PubMed ID: 20573082)
1. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.
Koolen SL; Oostendorp RL; Beijnen JH; Schellens JH; Huitema AD
Br J Clin Pharmacol; 2010 May; 69(5):465-74. PubMed ID: 20573082
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
3. A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development.
Yu H; Janssen JM; Sawicki E; van Hasselt JGC; de Weger VA; Nuijen B; Schellens JHM; Beijnen JH; Huitema ADR
J Clin Pharmacol; 2020 Mar; 60(3):340-350. PubMed ID: 31595980
[TBL] [Abstract][Full Text] [Related]
4. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors.
Oostendorp RL; Huitema A; Rosing H; Jansen RS; Ter Heine R; Keessen M; Beijnen JH; Schellens JH
Clin Cancer Res; 2009 Jun; 15(12):4228-33. PubMed ID: 19509162
[TBL] [Abstract][Full Text] [Related]
5. Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model.
Hendrikx JJ; Lagas JS; Song JY; Rosing H; Schellens JH; Beijnen JH; Rottenberg S; Schinkel AH
Int J Cancer; 2016 Feb; 138(3):758-69. PubMed ID: 26297509
[TBL] [Abstract][Full Text] [Related]
6. From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies.
Koolen SL; van Waterschoot RA; van Tellingen O; Schinkel AH; Beijnen JH; Schellens JH; Huitema AD
J Clin Pharmacol; 2012 Mar; 52(3):370-80. PubMed ID: 21505085
[TBL] [Abstract][Full Text] [Related]
7. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.
Bardelmeijer HA; Ouwehand M; Buckle T; Huisman MT; Schellens JH; Beijnen JH; van Tellingen O
Cancer Res; 2002 Nov; 62(21):6158-64. PubMed ID: 12414642
[TBL] [Abstract][Full Text] [Related]
8. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.
van Waterschoot RA; Lagas JS; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2010 Dec; 127(12):2959-64. PubMed ID: 21351274
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test.
Michael M; Cullinane C; Hatzimihalis A; O'Kane C; Milner A; Booth R; Schlicht S; Clarke SJ; Francis P
Cancer Chemother Pharmacol; 2012 Jan; 69(1):125-35. PubMed ID: 21626050
[TBL] [Abstract][Full Text] [Related]
10. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation.
Hendrikx JJ; Lagas JS; Wagenaar E; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Br J Cancer; 2014 May; 110(11):2669-76. PubMed ID: 24781280
[TBL] [Abstract][Full Text] [Related]
11. Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats.
Choi YH; Suh JH; Lee JH; Cho IH; Lee MG
J Pharm Pharmacol; 2010 Aug; 62(8):1084-8. PubMed ID: 20663044
[TBL] [Abstract][Full Text] [Related]
12. Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours.
Vermunt MAC; de Weger VA; Janssen JM; Lopez-Yurda MI; Keessen M; Thijssen B; Rosing H; Huitema ADR; Beijnen JH; Marchetti S
Drugs R D; 2021 Mar; 21(1):103-111. PubMed ID: 33464545
[TBL] [Abstract][Full Text] [Related]
13. Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
Engels FK; Mathot RA; Loos WJ; van Schaik RH; Verweij J
Cancer Biol Ther; 2006 Jul; 5(7):833-9. PubMed ID: 16775418
[TBL] [Abstract][Full Text] [Related]
14. Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir.
Yu H; Janssen JM; de Weger VA; Nuijen B; Stuurman RE; Marchetti S; Schellens JHM; Beijnen JH; Dorlo TPC; Huitema ADR
Invest New Drugs; 2020 Oct; 38(5):1526-1532. PubMed ID: 32306204
[TBL] [Abstract][Full Text] [Related]
15. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
Engels FK; Ten Tije AJ; Baker SD; Lee CK; Loos WJ; Vulto AG; Verweij J; Sparreboom A
Clin Pharmacol Ther; 2004 May; 75(5):448-54. PubMed ID: 15116057
[TBL] [Abstract][Full Text] [Related]
16. Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure.
Rudek MA; Chang CY; Steadman K; Johnson MD; Desai N; Deeken JF
Cancer Chemother Pharmacol; 2014 Apr; 73(4):729-36. PubMed ID: 24488374
[TBL] [Abstract][Full Text] [Related]
17. Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer.
Yu H; Hendrikx JJ; Rottenberg S; Schellens JH; Beijnen JH; Huitema AD
AAPS J; 2016 Mar; 18(2):362-71. PubMed ID: 26603889
[TBL] [Abstract][Full Text] [Related]
18. Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein- and cytochrome P4503A-mediated herb-drug interactions.
Lee JH; Shin YJ; Kim HJ; Oh JH; Jang YP; Lee YJ
Int J Pharm; 2011 May; 410(1-2):68-74. PubMed ID: 21421030
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer.
Slaviero KA; Clarke SJ; McLachlan AJ; Blair EY; Rivory LP
Br J Clin Pharmacol; 2004 Jan; 57(1):44-53. PubMed ID: 14678339
[TBL] [Abstract][Full Text] [Related]
20. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.
Choi JS; Piao YJ; Kang KW
Arch Pharm Res; 2011 Apr; 34(4):607-13. PubMed ID: 21544726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
